Yıl 2019,
Sayı: 2, 142 - 147, 01.06.2019
Öz
In oncology, the activity of monoclonal antibodies which known as immune checkpoint inhibitors is better understood every day. These drugs are efficaciousby inhibiting the inhibitory mechanisms in the immune system and their side effects can be defined as autoimmune events that caused by excessive immune response.. Immunerelated side effects are not very common and can usually be treated with steroids and dose modifications. Immunosuppressive treatments are used in resistant cases. Increasing the experience with these drugs will enable more effective treatment algorithms to be developed and a better understanding of the side effect profile
Anahtar Kelimeler
Kaynakça
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti- PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-91. (CrossRef)
- Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559-74. (CrossRef)
- Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2016;35:785-92. (CrossRef)
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. (CrossRef)
- h t t p : / / w w w . a c c e s s d a t a . f d a . g o v / d r u g s a t f d a _ d o c s / label/2017/761049s000lbl.pdf (Accessed on March 26, 2019).
- Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017;176:1649-52. (CrossRef)
- Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7. (CrossRef)
- Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161-9. (CrossRef)
- Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82. (CrossRef)
- Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64. (CrossRef)
- Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22.
- Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013; 23:47-54. (CrossRef)
- http://packageinserts.bms.com/pi/pi_opdivo.pdf (Accessed on March 26, 2019).
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44. (CrossRef)
- Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2:1607-16. (CrossRef)
- Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res 2016;22:6051-60. (CrossRef)
- Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98:1361-75. (CrossRef)
- Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine- related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21:371-81. (CrossRef)
- Blansfield JA1, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-8.
- Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29-38. (CrossRef)
- http://www.merck.com/product/usa/pi_circulars/k/keytruda/ keytruda_pi.pdf (Accessed on March 26, 2019).
- Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab- induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29:e237-40. (CrossRef)
- Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7:915-18. (CrossRef)
- Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90:638-47. (CrossRef)
- Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017;32:936-42. (CrossRef)
- Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol 2007; 5:70-4. (CrossRef)
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102-11. (CrossRef)
- DiGiacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58:1297-306. (CrossRef)
- Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain- Barré syndrome in a melanoma patient. Ann Oncol 2011; 22:991-3. (CrossRef)
- Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30:e76-8. (CrossRef)
- Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009; 58:1351-3. (CrossRef)
- Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009;32:322-4. (CrossRef)
- Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747-8. (CrossRef)
- Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) 2016;69:1751-63. (CrossRef)
- Cappelli LC, Naidoo J, Bingham CO 3rd, Shah AA. IInflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy 2017; 9:5-8. (CrossRef)
Yıl 2019,
Sayı: 2, 142 - 147, 01.06.2019
Öz
İmmün kontrol noktası inhibitörleri olarak bilinen monoklonal antikorların onkoloji alanındaki etkinlikleri hergeçen gün daha iyi anlaşılmaktadır. Bu ilaçlar immün sistem üzerindeki inhibitör mekanizmaların engellenmesi yoluyla etkinlik göstermektedirler ve yan etkileri de aşırı immün yanıt sonucu ortaya çıkan otoimmün olaylar olarak tanımlanabilir. İmmün aracılı yan etkiler çok sık olmamakla beraber ilacın kesilmesi ve streoid kullanımı ile genellikle gerilemektedir. Dirençli vakalarda immünsüpresif tedaviler kullanılmaktadır.Bu ilaçlar ile olan deneyimlerin artması daha etkili tedavi algoritmaları geliştirilebilmesine ve yan etki profilinin daha iyi anlaşılabilmesine olanak sağlayacaktır
Anahtar Kelimeler
Kaynakça
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti- PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-91. (CrossRef)
- Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559-74. (CrossRef)
- Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2016;35:785-92. (CrossRef)
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. (CrossRef)
- h t t p : / / w w w . a c c e s s d a t a . f d a . g o v / d r u g s a t f d a _ d o c s / label/2017/761049s000lbl.pdf (Accessed on March 26, 2019).
- Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017;176:1649-52. (CrossRef)
- Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7. (CrossRef)
- Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161-9. (CrossRef)
- Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82. (CrossRef)
- Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64. (CrossRef)
- Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22.
- Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013; 23:47-54. (CrossRef)
- http://packageinserts.bms.com/pi/pi_opdivo.pdf (Accessed on March 26, 2019).
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44. (CrossRef)
- Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2:1607-16. (CrossRef)
- Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res 2016;22:6051-60. (CrossRef)
- Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98:1361-75. (CrossRef)
- Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine- related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21:371-81. (CrossRef)
- Blansfield JA1, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-8.
- Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29-38. (CrossRef)
- http://www.merck.com/product/usa/pi_circulars/k/keytruda/ keytruda_pi.pdf (Accessed on March 26, 2019).
- Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab- induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29:e237-40. (CrossRef)
- Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7:915-18. (CrossRef)
- Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90:638-47. (CrossRef)
- Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017;32:936-42. (CrossRef)
- Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol 2007; 5:70-4. (CrossRef)
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102-11. (CrossRef)
- DiGiacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58:1297-306. (CrossRef)
- Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain- Barré syndrome in a melanoma patient. Ann Oncol 2011; 22:991-3. (CrossRef)
- Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30:e76-8. (CrossRef)
- Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009; 58:1351-3. (CrossRef)
- Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009;32:322-4. (CrossRef)
- Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747-8. (CrossRef)
- Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) 2016;69:1751-63. (CrossRef)
- Cappelli LC, Naidoo J, Bingham CO 3rd, Shah AA. IInflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy 2017; 9:5-8. (CrossRef)
Toplam 35 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Collection |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Haziran 2019 |
| Yayımlandığı Sayı | Yıl 2019Sayı: 2 |